Altman Peter purchased $2K of BCDA

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca

BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.

BioCardia (BCDA) reported Q2 2026 regulatory updates for its CardiAMP cell therapy and Helix delivery catheter. According to management, Japan’s PMDA supported a Shonin premarket submission, with approval expected about 12 months after filing. The FDA said CardiAMP Heart Failure 2 could support premarket approval and outlined two Helix clearance pathways. Q2 2026 net cash used in operations was ~$1.7M; cash ended at ~$5.4M.

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – August 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,

Conifer Management, L.L.C. purchased 273,712 indirectly-held shares of GROUP 1 AUTOMOTIVE INC (GPI) at an average of $242.15 ($235.63–$250.35, $66.28M total) across 29 trades over 2026-09-28 to 2026-09-30.

KAMFAR RAMIN purchased 425,590 indirectly-held shares of Bluerock Private Real Estate Fund (BPRE) at an average of $12.57 ($12.50–$12.61, $5.35M total) across 3 trades over 2026-09-28 to 2026-09-30.